The pharmaceutical inspection machines market grew from USD 1.06 billion in 2024 to USD 1.15 billion in 2025, and is projected to reach USD 1.66 billion by 2030, growing at a CAGR of 7.72 percent, according to a new report from ResearchAndMarkets.

The report highlighted that the sector is undergoing rapid transformation, driven by digital transformation, regulatory pressures, and increased demand for production agility.

Manufacturers are increasingly adopting modular designs and data analytics to realize continuous improvement, process agility, and ease of adaptation for evolving therapies.

However, 2025 has brought fresh challenges. Newly imposed US tariffs on select electronic components and sensors have increased capital expenditures for pharmaceutical inspection machinery that relies on international supply. This has prompted a shift in sourcing toward domestic and regional partners.

To offset elevated costs and maintain equipment availability, companies are embracing value engineering, reconfigured assemblies, and greater focus on local manufacturing partnerships.

The report underscored that robust risk management and agile procurement are now critical to ensuring steady access to inspection systems while preserving budget targets and compliance standards.

Key players in the pharmaceutical inspection machines market include Mettler-Toledo International Inc., Thermo Fisher Scientific Inc., Sartorius AG, Syntegon Technology GmbH, Krones AG, Ishida Co. Ltd., ProMach Inc., Coesia S.p.A., Seidenader Maschinenbau GmbH, and Loma Systems Ltd.